Latest action: Passed Senate with an amendment by Voice Vote. (consideration: CR S4425-4426; text: CR S4425-4426)
Originating chamber has voted to pass. Sent to the other chamber.
The Senate voted to pass the bill. It now moves to the House, which repeats the committee referral and floor-vote process.
Next: Passed Both Chambers
Conference committee (if versions differ), then the President
Reauthorizes programs to speed up access to treatment options for ALS patients.
The problem
ALS patients need faster access to new therapies. Current approval processes may delay life-saving treatments from reaching people with this fatal disease.
The proposal
The bill extends and renews existing programs designed to accelerate how quickly ALS treatments can be developed, tested, and made available to patients.
The impact
ALS patients, researchers, and pharmaceutical companies developing treatments are affected. Patients may gain faster access to new therapies.
Accelerating therapies could help ALS patients get new treatments sooner. This may improve outcomes and quality of life for people with this serious disease.
Streamlined approval processes may encourage companies to develop more ALS treatments. More research could lead to better options for patients.
Faster pathways reward companies that invest in ALS research. This can attract more resources to finding solutions for rare diseases.
Accelerating approval processes could mean less testing. Treatments approved faster might have unknown side effects or risks not fully studied.
New treatments may be expensive or only available to some patients. Not everyone with ALS might benefit equally from faster approvals.
No official summary exists for this bill. It's unclear exactly what programs are being reauthorized or what changes are made.
Generated by AI from the bill text. Not a prediction and not legal or policy advice. The percentage is the model's own rating of each item — self-reported, and not a measure of how accurate it is.
Loading map…
Loading...
0 citizens have already voted
Free · No spam · See how your representatives voted
Be the first to weigh in
Your vote starts the conversation
How citizen engagement works
Citizens vote & comment
Public opinion data is aggregated and updated in real time.
Patterns become visible
Representatives can see constituent sentiment broken down by district.
Your voice on the record
Contact your rep directly — one constituent call can shift a staffer's priority list.
Research shows that constituent contacts — especially calls — are among the most effective ways to influence a legislator's position on active bills.
Individual contributions, grouped by employer · FEC
Where their individual donors work · 2026 cycle
Money from people who work there, not from the company. Not tied to this bill.
Itemized individual contributions via FEC, grouped by the employer each contributor self-reported. Companies and unions cannot contribute to federal candidates from their treasuries, so these totals are money from people who work at an employer — never from the organization itself. They are campaign contributions covering a full election cycle and are not connected to this bill.
Senate LDA lobbying disclosures
Couldn't load lobbying disclosures right now.